Abstract
BackgroundMiRNAs that are potential biomarkers for predicting prognosis for acute myeloid leukemia (AML) have been identified. However, comprehensive analyses investigating the association between miRNA expression profiles and AML survival remain relatively deficient.MethodIn the present study, we performed multivariate Cox’s analysis and principal component analysis (PCA) using data from The Cancer Genome Atlas (TCGA) to identify potential molecular signatures for predicting non-M3 AML prognosis.ResultWe found that patients who were still living were significantly younger at diagnosis than those who had died (P = 0.001). In addition, there was a marked difference in living status among different risk category groups (P = 0.022). A multivariate Cox model suggested that three miRNAs were potential biomarkers of non-M3 AML prognosis, including miR-181a-2, miR-25 and miR-362. Subsequently, PCA analyses were conducted to comprehensively represent the expression levels of these three miRNAs in each patient with a PCA value. According to the log-rank test, AML outcome for patients with lower PCA values was significantly different from those with higher PCA values (P < 0.001). Further bioinformatic analysis revealed the biological functions of the selected miRNAs.ConclusionWe conducted a comprehensive analysis of TCGA non-M3 AML data, identifying three miRNAs that are significantly correlated with AML survival. PCA values for the identified miRNAs are valuable for predicting AML prognosis.
Highlights
MiRNAs that are potential biomarkers for predicting prognosis for acute myeloid leukemia (AML) have been identified
AML dataset in the The Cancer Genome Atlas (TCGA) database MiRNA-seq data for 705 miRNAs and clinical data for AML patients were downloaded from the TCGA data portal, an interactive data system for researchers to query, download, upload, and analyse harmonized cancer genomic data sets
Association between clinical factors and AML survival Relative data were downloaded from TCGA database
Summary
MiRNAs that are potential biomarkers for predicting prognosis for acute myeloid leukemia (AML) have been identified. Comprehensive analyses investigating the association between miRNA expression profiles and AML survival remain relatively deficient. It is a haematological malignancy that is promoted by various factors, including environmental exposure and several abnormality in cellular and molecular level [1]. Studies have demonstrated that several biological factors may be involved in the pathogenesis and MicroRNAs (miRNAs), small noncoding RNA species approximately 22 nucleotides in length, have been demonstrated to play a predominant role in translational and post-transcriptional regulation. MiRNAs participate in a wide range of biological processes, and their expression levels are frequently abnormal in human cancers [2]. Expression levels of miRNA have been identified as potential biomarkers for predicting prognosis in various
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
